ПРОТЕОМНЫЕ ИССЛЕДОВАНИЯ ПРИ АТЕРОСКЛЕРОЗЕ
https://doi.org/10.15372/ATER20180309
Аннотация
Обзор посвящен анализу литературных данных, связанных с ролью протеомных исследований при изучении атеросклеротических сердечно-сосудистых заболеваний. Приводятся результаты исследований по поиску новых протеомных потенциальных биомаркеров коронарного атеросклероза, ишемической болезни сердца, острого коронарного синдрома, инфаркта миокарда, атеросклероза сонных артерий, а также протеомных маркеров нестабильной атеросклеротической бляшки. Обсуждается, что протеомный анализ является перспективной развивающейся областью исследований.
Об авторах
Ю. И. Рагино
НИИТПМ - филиал ИЦиГ СО РАН
Россия
Россия
Е. М. Стахнёва
НИИТПМ - филиал ИЦиГ СО РАН
Россия
Россия
Список литературы
1. Арчаков А.И. Биоинформатика, геномика и протеомика - науки о жизни XXI столетия // Вопр. мед. химии. 2000. № 1. С. 13-18.
2. http://www.plasmaproteomedatabase.org
3. Addona T.A., Abbatiello S.E., Schilling B. et al. Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma // Nat. Biotechnol. 2009. Vol. 27, N 7. P. 633-641.
4. Xia J.Q., Sedransk N., Feng X. Variance component analysis of a multi-site study for the reproducibility of multiple reaction monitoring measurements of peptides in human plasma // PLoS One. 2011. Vol. 6, N 1. P. e14590.
5. Ganz P., Heidecker B., Hveem K. et al. Development and validation of a protein based risk score for cardiovascular outcomes among patients with stable coronary heart disease // JAMA. 2016. Vol. 315, N 23. P. 2532-2541.
6. Wang G., Mathew A.V., Yu H. et al. Myeloperoxidase mediated HDL oxidation and HDL proteome changes do not contribute to dysfunctional HDL in Chinese subjects with coronary artery disease // PLoS One. 2018. Vol. 13, N 3. P. e0193782.
7. V A., Nayar P.G., Murugesan R. et al. A systems biology and proteomics-based approach identifies SRC and VEGFA as biomarkers in risk factor mediated coronary heart disease // Mol. Biosyst. 2016. Vol. 12, N 8. P. 2594-2604.
8. Krishnan S., Huang J., Lee H. et al. Combined High-Density Lipoprotein Proteomic and Glycomic Profiles in Patients at Risk for Coronary Artery Disease // J. Proteome Res. 2015. Vol. 14, N 12. P. 5109-5118.
9. Cao D.J., Hill J.A. Copper Futures. Ceruloplasmin and Heart Failure // Circ. Res. 2014. Vol. 114. P. 1678-1680.
10. Cabassi A., Binno S.M., Tedeschi S. Low Serum ferroxidase activity is associated with mortality in heart failure and related to both peroxynitrite-induced cysteine oxidation and tyrosine nitration of ceruloplasmin // Circ. Res. 2014. Vol. 114. P. 1723-1732.
11. Lepedda A.J., Lobina O., Rocchiccioli S. et al. Identification of differentially expressed plasma proteins in atherosclerotic patients with type 2 diabetes // J. Diabetes Compl. 2016. Vol. 30, N 5. P. 880-886.
12. Shan L., Pang L., Zhang R. et al. PCSK9 binds to multiple receptors and can be functionally inhibited by an EGF-A peptide // Biochem. Biophys. Res. Commun. 2008. Vol. 375, N 1. P. 69-73.
13. Ljungberg J., Janiec M., Bergdahl I.A. et al. Proteomic biomarkers for incident aortic stenosis requiring valvular replacement // Circulation. 2018. pii: CIRCULATIONAHA. 117.030414. DOI: 10.1161/CIRCULATIONAHA. 117.030414.
14. Langley S.R., Willeit K., Didangelos A. et al. Extracellular matrix proteomics identifies molecular signature of symptomatic carotid plaques // J. Clin. Invest. 2017. Vol. 127, N 4. P. 1546-1560.
15. Lind L., Ärnlöv J., Lindahl B. et al. Use of a proximity extension assay proteomics chip to discover new biomarkers for human atherosclerosis // Atherosclerosis. 2015. Vol. 242, N 1. P. 205-210.
16. Patzelt J., Verschoor A., Langer H.F. Platelets and the complement cascade in atherosclerosis // Front. Physiol. 2015. Vol. 6. P. 49-54.
17. Stakhneva E.M., Meshcheryakova I.A., Demidov E.A. et al. Proteomic study of blood serum in coronary atherosclerosis // Bull. Exp. Biol. Med. 2017. Vol. 162, N 3. P. 343-345.
18. Yasojima K., Schwab C., McGeer E.G., McGeer P.L. Generation of C-reactive protein and complement components in atherosclerotic plaques // Am. J. Pathol. 2001. Vol. 158, N 3. P. 1039-1051.
19. De Hoog V.C., Timmers L., Schoneveld A.H. et al. Serum extracellular vesicle protein levels are associated with acute coronary syndrome // Eur. Heart J. Acute Cardiovasc. Care. 2013. Vol. 2, N 1. P. 53-60.
20. Yin X., Subramanian S., Hwang S.J. et al. Protein biomarkers of new-onset cardiovascular disease: prospective study from the systems approach to biomarker research in cardiovascular disease initiative // Arterioscler. Thromb. Vasc. Biol. 2014. Vol. 34, N 4. P. 939-945.
21. Haas B., Serchi T., Wagner D.R. et al. Proteomic analysis of plasma samples from patients with acute myocardial infarction identifies haptoglobin as a potential prognostic biomarker // J. Proteomics. 2011. Vol. 75, N. 1. P. 229-236.
22. Raizada A., Bhandari S., Khan M.A. et al. Brain type natriuretic peptide (BNP)-A marker of new millennium in diagnosis of congestive heart failure // Indian J. Clin. Biochem. 2007. Vol. 22, N 1. P. 4-9.
23. Xu X., Li Z., Gao W. Growth differentiation factor 15 in cardiovascular diseases: from bench to bedside // Biomarkers. 2011. Vol. 16, N 6. P. 466-475.
24. Schiopu A., Cotoi O.S. S100A8 and S100A9: DAMPs at the crossroads between innate immunity, traditional risk factors, and cardiovascular disease // Mediators Inflamm. 2013. Vol. 828, N 3. P. 54-61.
25. Navas-Carrillo D., Marнn F., Valdés M., Orenes-Piсero E. Deciphering acute coronary syndrome biomarkers: High-resolution proteomics in platelets, thrombi and microparticles // Crit. Rev. Clin. Lab. Sci. 2017. Vol. 54. N 1. P. 49-58.
26. Basak T., Varshney S., Akhtar S., Sengupta S. Understanding different facets of cardiovascular diseases based on model systems to human studies: a proteomic and metabolomic perspective // J. Proteomics. 2015. Vol. 127 (Pt A). P. 50-60.
27. Sentman M.L., Granström M., Jakobson H. et al. Phenotypes of mice lacking extracellular superoxide dismutase and copper- and zinc-containing superoxide dismutase// J. Biol. Chem. 2006. Vol. 281, N 11. P. 6904-6909.
28. Rao N.M., Capri J., Cohn W. et al. Peptide composition of stroke causing emboli correlate with serum markers of atherosclerosis and inflammation // Front. Neurol. 2017. Vol. 8. P. 427-431.
29. Lepedda A.J., Nieddu G., Zinellu E. et al. Proteomic analysis of plasma-purified VLDL, LDL, and HDL fractions from atherosclerotic patients undergoing carotid endarterectomy: identification of serum amyloid A as a potential marker // Oxidat. Med. and Cell. Long. 2013. Vol. 38, N 5. P. 214-225.
30. Herrington D.M., Mao C., Parker S.J. et al. Proteomic Architecture of Human Coronary and Aortic Atherosclerosis // Circulation. 2018. Vol. 137, N 25. P. 2741-2756.
31. Han Y., Zhao S., Gong Y. et al. Serum cyclin-dependent kinase 9 is a potential biomarker of atherosclerotic inflammation // Oncotarget. 2016. Vol. 7, N 2. P. 1854-1862.
32. Lepedda A.J., Cigliano A., Cherchi G.M. et al. A proteomic approach to differentiate histologically classified stable and unstable plaques from human carotid arteries // Atherosclerosis. 2009. Vol. 203, N 1. P. 112-118.
33. Olson F.J., Sihlbom C., Davidsson P. et al. Consistent differences in protein distribution along the longitudinal axis in symptomatic carotid atherosclerotic plaques // Biochem. Biophys. Res. Commun. 2010. Vol. 401, N 4. P. 574-580.
34. Rocchiccioli S., Pelosi G., Rosini S. et al. Secreted proteins from carotid endarterectomy: an untargeted approach to disclose molecular clues of plaque progression // J. Transl. Med. 2013. Vol. 11. P. 260-267.
Рецензия
Для цитирования:
Рагино Ю.И., Стахнёва Е.М. ПРОТЕОМНЫЕ ИССЛЕДОВАНИЯ ПРИ АТЕРОСКЛЕРОЗЕ. Атеросклероз. 2018;14(3):56-63. https://doi.org/10.15372/ATER20180309
For citation:
Ragino Yu.I., Stakhneva E.M. PROTEOMIC STUDIES IN ATHEROSCLEROSIS. Ateroscleroz. 2018;14(3):56-63. (In Russ.) https://doi.org/10.15372/ATER20180309
Просмотров:
271
Послать статью по эл. почте 